Rosen Law Firm Launches Investigations into Soleno and Edwards Lifesciences
New York, Thursday, 16 October 2025.
Rosen Law Firm is investigating potential securities violations at Soleno Therapeutics and fiduciary breaches at Edwards Lifesciences, impacting investor confidence and raising corporate governance concerns.
Background to the Investigations
On October 15, 2025, Rosen Law Firm, a leading global investor rights law firm, announced investigations into potential securities violations involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) and breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW) [1][2]. The firm is renowned for its expertise in securities class actions, having achieved significant settlements in the past, including the largest against a Chinese company [2]. These investigations are pivotal as they address critical issues of corporate governance and financial accountability, potentially impacting investor confidence in both companies.
Soleno Therapeutics Under Scrutiny
The investigation into Soleno Therapeutics follows allegations that the company may have issued materially misleading business information to the investing public. This concern was heightened by a report from Scorpion Capital in August 2025, which questioned the safety of Soleno’s Prader-Willi syndrome treatment, VYKAT XR. The report suggested that the drug might face withdrawal from the market or a decline in new prescriptions, leading to significant stock price declines [1]. On August 15, 2025, Soleno’s stock fell by 7.4%, followed by an additional drop of 4.9% the next trading day [1].
Edwards Lifesciences: Breaches of Fiduciary Duties
Simultaneously, Edwards Lifesciences is under investigation for potential breaches of fiduciary duties by its directors and officers. Such breaches could involve failures to act in the best interest of shareholders, potentially leading to significant financial losses for investors [2]. The Rosen Law Firm encourages current shareholders to engage with the investigation process actively, highlighting the importance of holding corporate leaders accountable for their actions.
Implications for Investors and the Market
These investigations are significant not only for the companies involved but also for the broader market as they underscore the essential role of transparency and accountability in corporate governance. Investors are urged to monitor developments closely, as outcomes from these investigations could lead to legal actions, financial penalties, and changes in corporate policies [1][2]. The ongoing scrutiny also serves as a reminder of the critical importance of robust regulatory compliance and ethical leadership in preserving investor trust and market integrity.